ArticleFrontiers in endocrinology2025
The threshold effect of fasting blood glucose levels on the risk of delivering macrosomia in gestational diabetes mellitus patients.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prenatal Benzydamine Exposure Induces Fetal Growth Restriction and Maternal Oxidative Stress in Rats.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gestational diabetes mellitus (GDM) is a prevalent condition during pregnancy, and macrosomia is a recognized risk associated with it. However, the specific relationship between fasting blood glucose (FBG) levels and the risk of macrosomia in GDM, particularly any potential thresholds for this relationship, remains unclear. Methods: This retrospective cohort study analyzed data from 7,957 pregnant women who underwent antenatal care and delivered at The First People's Hospital of Shangqiu between February 1, 2018, and December 30, 2022. Participants were stratified into three groups based on FBG levels: <5.1 mmol/L, 5.1-7 mmol/L, and ≥7 mmol/L. Multivariable logistic regression analyses were performed to assess the association between FBG levels and the risk of macrosomia. Two-piecewise regression models were applied to identify a threshold for the FBG-macrosomia relationship. Results: The prevalence of macrosomia increased substantially with increasing FBG levels (P < 0.001). The adjusted multivariable logistic regression analyses revealed that compared to women with FBG levels <5.1 mmol/L, those with FBG levels of 5.1-7 mmol/L and ≥7 mmol/L had 4.69 (95% CI: 4.06-5.42) and 8.65 (95% CI: 7.31-10.23) times higher risk of macrosomia, respectively (both P < 0.001). Two-piecewise regression models identified a threshold of 8.037 mmol/L. Below this threshold, each unit increase in FBG was associated with a 1.93-fold increase in the odds of macrosomia (95% CI: 1.83-2.04, P < 0.001). Above this threshold, the association was no longer statistically significant (OR = 1.04, 95% CI: 0.90-1.21, P = 0.587). Furthermore, the stratified analysis also showed a positive association between FBG level and macrosomia. Conclusion: There is a nonlinear relationship between FBG levels during pregnancy and the risk of macrosomia in GDM women, with a potential threshold effect at 8.037 mmol/L. Below the threshold, macrosomia prevalence markedly rises with elevated FBG levels, whereas above it, the association loses significance, implying a potential saturation at very high glucose levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.